Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study

• DOI: 10.1371/journal.pone.0279747
• Publication Date: 2022-12-30T18:53:49Z
• Authors: Takuya Ogawa; Yuta Kajiyama; Hideaki Ishido; Shigeru Chiba; Gajanan S. Revankar; Tomohito Nakano; Seira Taniguchi; Takashi Kanbayashi; Kensuke Ikenaka; Hideki Mochizuki
• Keywords: Orexin-A; Interquartile range

Patients with Parkinson's disease (PD) often suffer from sleep disturbances, including excessive daytime sleepiness (EDS) and rapid eye movement behavior disorder (RBD). These symptoms are also experienced by patients narcolepsy, which is characterized orexin neuronal loss. In PD, a decrease in neurons observed pathologically, but the association between disturbance PD cerebrospinal fluid (CSF) levels still unclear. This study aimed to clarify role of as biomarker PD. CSF samples were obtained previous cohort conducted 2015 2020. We cross-sectionally longitudinally examined levels, sleep, clinical characteristics. analyzed 78 58 21 controls. (median = 272.0 [interquartile range 221.7-334.5] pg/mL) lower than those controls (352.2 [296.2-399.5] pg/mL, p 0.007). There no significant differences according EDS, RBD, or use dopamine agonists. Moreover, correlation was characteristics multiple linear regression analysis. Furthermore, longitudinal changes not correlated showed decreased these did show any Our results suggest limited efficacy for that disturbances may be affected dysfunction nervous system other orexin, dopaminergic treatments Understanding reciprocal among neurotransmitters provide better treatment strategy